Abstract
In this paper, we report findings from a family-based association study examining the association between polymorphisms in two key estrogen-metabolism genes CYP1B1 (codon 432 G → C and codon 453 A → G variants) and COMT (codon 158 G → A variant) and female breast cancer. We conducted the study among 280 nuclear families containing one or more daughters with breast cancer with a total of 1124 family members (702 with available constitutional DNA and questionnaire data and 421 without). These nuclear families were selected from breast cancer families participating in the Metropolitan New York Registry (MNYR) — one of the six centers of NCI's Breast Cooperative Family Registry. We used likelihood-based statistical methods to examine the allelic associations. We found none of the variant alleles of the CYP1B1 and COMT genes to be associated with breast cancer in these families. This was consistent with results from matched case-control analyses using all available sib-ships in these families. However, we found that parental carrier status of the CYP1B1 codon 453 variant G allele and the COMT codon 158 variant A allele was associated with breast cancer risk in daughters (independent of the daughters' own genotype). In conclusion, findings from this family-based study indicate that a woman's own CYP1B1 or COMT genotypes are not associated with her breast cancer risk. Although the study found that parental carrier status of certain CYP1B1 or COMT genotypes might be associated with daughter's breast cancer risk, the biological basis as well as independent confirmation of this finding need to be investigated in future larger family-based studies before making meaningful inferences.
Similar content being viewed by others
References
Service RF: New role for estrogen in cancer? Science 279: 1631–1633, 1998
Jan ST, Devanesan PD, Stack DE, Ramanathan R, Byun J, Gross ML, Rogan EG, Cavalieri EL: Metabolic activation and formation of DNA adducts of hexestrol, a synthetic nonsteroidal carcinogenic estrogen. Chem Res Toxicol 11: 412–419, 1998
Sutter TR, Tang YM, Hayes CL, Wo YY, Jabs EW, Li X, Yin H, Cody CW, Greenlee WF: Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem 269: 13092–13099, 1994
McKay JA, Melvin WT, Ah-See AK, Ewen SW, Greenlee WF, Marcus CB, Burke MD, Murray GI: Expression of cytochrome P450 CYP1B1 in breast cancer. FEBS Lett 374: 270–272, 1995
Taylor MC, McKay JA, Murray GI, Greenlee WF, Marcus CB, Burke MD, Melvin WT: Cytochrome P450 1B1 expression in humanmalignant tumours. Biochem Soc Trans 24: 328S, 1996
Spink DC, Spink BC, Cao JQ, DePasquale JA, Pentecost BT, Fasco MJ, Li Y, Sutter TR: Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 19: 291–298, 1998
Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, Melvin WT: Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57: 3026–3031, 1997
Tang YM, Wo YY, Stewart J, Hawkins AL, Griffin CA, Sutter TR, Greenlee WF: Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J Biol Chem 271: 28324–28330, 1996
Bailey LR, Roodi N, Dupont WD, Parl FF: Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 58: 5038–5041, 1998
Zheng W, Xie DW, Jin F, Cheng JR, Dai Q, Wen WQ, Shu XO, Gao YT: Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 9: 147–150, 2000
Watanabe J, Shimada T, Gillam EM, Ikuta T, Suemasu K, Higashi Y, Gotoh O, Kawajiri K: Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 10: 25–33, 2000
Kocabas NA, Sardas S, Cholerton S, Daly AK, Karakaya AE: Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. Arch Toxicol 76: 643–649, 2002
Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J: Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34: 4202–4210, 1995
Lavigne JA, Helzlsouer KJ, Huang HY, Strickland PT, Bell DA, Selmin O, Watson MA, Hoffman S, Comstock GW, Yager JD: An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 57: 5493–5497, 1997
Thompson PA, Shields PG, Freudenheim JL, Stone A, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Kadlubar FF, Ambrosone CB: Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res 58: 2107–2110, 1998
Millikan RC, Pittman GS, Tse CK, Duell E, Newman B, Savitz D, Moorman PG, Boissy RJ, Bell DA: Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis 19: 1943–1947, 1998
Goodman JE, Lavigne JA, Wu K, Helzlsouer KJ, Strickland PT, Selhub J, Yager JD: COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk. Carcinogenesis 22: 1661–1665, 2001
Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY: Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 59: 4870–4875, 1999
Yim DS, Parkb SK, Yoo KY, Yoon KS, Chung HH, Kang HL, Ahn SH, Noh DY, Choe KJ, Jang IJ, Shin SG, Strickland PT, Hirvonen A, Kang D: Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer. Pharmacogenetics 11: 279–286, 2001
Matsui A, Ikeda T, Enomoto K, Nakashima H, Omae K, Watanabe M, Hibi T, Kitajima M: Progression of human breast cancers to the metastatic state is linked to genotypes of catechol-O-methyltransferase. Cancer Lett 150: 23–31, 2000
Hamajima N, Matsuo K, Tajima K, Mizutani M, Iwata H, Iwase T, Miura S, Oya H, Obata Y: Limited association between a catechol-O-methyltransferase (COMT) polymorphism and breast cancer risk in Japan. Int J Clin Oncol 6: 13–18, 2001
Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Kang D, Vainio H, Uusitupa M, Hirvonen A: Polymorphic catechol-O-methyltransferase gene and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10: 635–640, 2001
Bergman-Jungestrom M, Wingren S: Catechol-O-Methyltransferase (COMT) gene polymorphism and breast cancer risk in young women. Br J Cancer 85: 859–862, 2001
Sanderson M, Williams MA, Daling JR, Holt VL, Malone KE, Self SG, Moore DE: Maternal factors and breast cancer risk among young women. Paediatr Perinat Epidemiol 12: 397–407, 1998
Weiss HA, Potischman NA, Brinton LA, Brogan D, Coates RJ, Gammon MD, Malone KE, Schoenberg JB: Prenatal and perinatal risk factors for breast cancer in young women. Epidemiology 8: 181–187, 1997
Ekbom A, Hsieh CC, Lipworth L, Adami HQ, Trichopoulos D: Intrauterine environment and breast cancer risk in women: a population-based study. J Natl Cancer Inst 89: 71–76, 1997
Potischman N, Troisi R: In-utero and early life exposures in relation to risk of breast cancer. Cancer Causes Control 10: 561–573, 1999
Ekbom A, Trichopoulos D, Adami HO, Hsieh CC, Lan SJ: Evidence of prenatal influences on breast cancer risk. Lancet 340: 1015–1018, 1992
Sanderson M, Williams MA, Malone KE, Stanford JL, Emanuel I, White E, Daling JR: Perinatal factors and risk of breast cancer. Epidemiology 7: 34–37, 1996
Ahsan H, Chen Y, Whittemore AS, Senie RT, Hamilton SP, Wang Q, Gurvich I, Santella RM: Variants in estrogenbiosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study (submitted for publication)
Hsu TM, Chen X, Duan S, Miller RD, Kwok PY: Universal SNP genotyping assay with fluorescence polarization Detection. Biotechniques 31: 560, 562, 564-560,8, passim, 2001
Chen X, Levine L, Kwok PY: Fluorescence polarization in homogeneous nucleic acid analysis. Genome Res 9: 492–498, 1999
Tu IP, Balise RR, Whittemore AS: Detection of disease genes by use of family data. II. Application to nuclear families. Am J Hum Genet 66: 1341–1350, 2000
Whittemore AS, Tu IP: Detection of disease genes by use of family data. I. Likelihood-based theory. Am J Hum Genet 66: 1328–1340, 2000
Spielman RS, McGinnis RE, Ewens WJ: Transmission test for linkage disequilibrium: the insulin gene region and insulindependent diabetes mellitus (IDDM). Am J Hum Genet 52: 506–516, 1993
Schaid DJ: General score tests for associations of genetic markers with disease using cases and their parents. Genet Epidemiol 13: 423–449, 1996
Spielman RS, Ewens WJ: The TDT and other family-based tests for linkage disequilibrium and association. Am J Hum Genet 59: 983–989, 1996
Hosmer D, Lemeshow S: Logistic Regression for Matched Case-Control Studies. Applied Logistic Regression, John Wiley & Sons, New York, 1989, pp 187–213
Breslow NE, Day NE: Statistical Methods in Cancer Research.-The Analysis of Case-Control Studies. Vol. I, IARC Sci. Publ. 1980, pp. 5–338
De VI, Hankinson SE, Li L, Colditz GA, Hunter DJ: Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 11: 489–492, 2002
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ahsan, H., Chen, Y., Whittemore, A.S. et al. A Family-based Genetic Association Study of Variants in Estrogen-metabolism Genes COMT and CYP1B1 and Breast Cancer Risk. Breast Cancer Res Treat 85, 121–131 (2004). https://doi.org/10.1023/B:BREA.0000025401.60794.68
Issue Date:
DOI: https://doi.org/10.1023/B:BREA.0000025401.60794.68